AION Labs launches CombinAble.AI to design antibodies for therapeutic development

The article discusses the launch of a new startup company called CombineAble.AI by AION Labs, an Israel-based AI-enabled drug discovery partnership. The startup aims to accelerate the development of therapeutics by tackling challenges related to antibody design through the integration of AI and computational methods for biomolecule simulations. Dr. Daria Kokh, the co-founder and CEO of CombineAble.AI, emphasizes the importance of combining advanced machine learning models to improve targeted antibody discovery, with support from AION Labs and its pharma partners.

Highlights of the article:
1. CombineAble.AI is formed as a result of AION Labs’ startup challenge to develop an AI-based solution for therapeutic antibodies.
2. The startup will leverage data from AION Labs’ pharma partners and publicly available data to develop a platform integrating AI and computational methods for biomolecule simulations.
3. Dr. Daria Kokh highlights the collaboration with AION Labs and its pharmaceutical partners as crucial for the scientific strategy and commercialization of CombineAble.AI’s solution.

Summary:
The article focuses on the launch of CombineAble.AI, a new startup by AION Labs, which aims to use AI and computational methods to accelerate the development of therapeutics by addressing challenges in antibody design. Dr. Daria Kokh emphasizes the importance of collaboration with AION Labs and its pharmaceutical partners in shaping the scientific strategy and commercialization of the startup’s solution.

Editorial content by NewsSIP AI